There are currently 71 active clinical trials seeking participants for Type 1 Diabetes research studies. The states with the highest number of trials for Type 1 Diabetes participants are California, Texas, Florida and Colorado.
GO TEAM: Glucose Optimization Through Technology Assisted Management
NCT06074458
Recruiting
Black/African American children and young adults with type 1 diabetes are less likely to use diabetes technologies, such as continuous glucose monitors, insulin pumps, and automated insulin delivery systems, compared to White children and young adults. The investigators are working to find ways to make sure that all patients with type 1 diabetes are equally able to use these technologies. The purpose of this study is to find out if a new computer program for the diabetes team, along with a smart... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
02/10/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Type 1 Diabetes
Register for Updates
Effect of C-peptide on Hypoglycemic Counterregulation
NCT06470295
Recruiting
Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hy... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
01/07/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Hypoglycemia, Type 1 Diabetes
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400005, San Francisco, California +24 locations
Conditions: Type 1 Diabetes
Register for Updates
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Kaiser Permanente Bonita Medical Offices, Bonita, California +80 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Sansum Diabetes Research Institute, Goleta, California +147 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
NCT05414409
Recruiting
Obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with obesity as well as potential mechanisms to modify disease.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
06/18/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Type 1 Diabetes, Obesity
Register for Updates
ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes
NCT04933851
Recruiting
This research will compare a psychological intervention ("ACT1VATE") versus diabetes self-management education and support (DSME/S; usual care) in improving clinical, behavioral, psychosocial, process, and cost outcomes among adults with poorly controlled type 1 diabetes (T1D) who are experiencing significant diabetes-related emotional distress and poor glycemic control in a real world, healthcare environment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Scripps Whittier Diabetes Institute, San Diego, California
Conditions: Type 1 Diabetes
Register for Updates
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05822609
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Register for Updates
Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial
NCT06981234
Recruiting
The goal of this study is to learn about the effect of the study drug acetazolamide in individuals with Type 1 Diabetes. Specifically, whether acetazolamide provides benefits to the kidneys while minimizing any side effects of the drug. These changes will be measured by laboratory tests that tell us how well the kidneys are functioning.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California
Conditions: Type 1 Diabetes
Register for Updates
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
NCT05065372
Recruiting
Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range. Yet, type 1 diabetes is a complex disease with pathophysiology that extends beyond beta-cell injury and insulin deficiency to include insulin resistance and renal vascular resistance, factors that accelerate cardiovascular disease risk. We have shown that metformin improved... Read More
Gender:
ALL
Ages:
Between 12 years and 25 years
Trial Updated:
06/10/2025
Locations: Children's Hospital Colorado/University of Colorado Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Register for Updates
Extended Bolus for Meals in a Closed-loop System
NCT05454891
Recruiting
This study aims to evaluate whether the use of an extended bolus will improve glucose control with high-fat high protein meals using a closed-loop system. The new knowledge gained from this study may provide a method to allow for the proper administration of insulin over an extended period to mitigate the risk of prolonged hyperglycemia or early hypoglycemia.
Gender:
ALL
Ages:
Between 13 years and 19 years
Trial Updated:
06/09/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Type 1 Diabetes
Register for Updates
Description of Patients With Type 1 Diabetes Treated With Teplizumab
NCT06892002
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Atlanta Diabetes Associates, Atlanta, Georgia +4 locations
Conditions: Type 1 Diabetes
Register for Updates